t} is not allowed`)}),o)})),preventStringArgument("setTimeout",0),preventStringArgument("setInterval",0))}catch(e){window?.viewerModel?.mode.debug&&console.error(e);const t=new Error("TB006");window.fedops?.reportError(t,"security_overrideGlobals"),window.Sentry?window.Sentry.captureException(t):globalThis.defineStrictProperty("sentryBuffer",[t],window,!1)}performance.mark("overrideGlobals ended")})(); //# sourceMappingURL=https://static.parastorage.com/services/wix-thunderbolt/dist/overrideGlobals.inline.45eeaad6.bundle.min.js.map
top of page

GPCR News 

Post: Blog2_Post

Exploring pharmacological inhibition of G q/11 as an analgesic strategy

Writer's picture: GPCR NewsGPCR News

Updated: Sep 22, 2022

August 2022


"Background and purpose: Misuse of opioids has greatly affected our society. One potential solution is to develop analgesics that act at targets other than opioid receptors. These can be used either as stand-alone therapeutics or to improve the safety profile of opioid drugs. Previous research showed that activation of Gq/11 proteins by G-protein coupled receptors has pro-nociceptive properties, suggesting that blockade of Gq/11 signalling could be beneficial for pain control. The aim of this study was to test this hypothesis pharmacologically by using potent and selective Gq/11 inhibitor YM-254890.


Experimental approach: We used a series of behavioural assays to evaluate the acute responses of mice to painful thermal stimulation while administering YM-254890 alone and in combination with morphine. We then used electrophysiological recordings to evaluate the effects of YM-254890 on the excitability of dorsal root ganglion (DRG) nociceptor neurons."




Recent Posts

See All

Comments


Powered by


All Rights Reserved © 2020 - 2024

Dr. GPCR CORP is a 501(c)(3) non profit organization

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
bottom of page